EP-1320: Postoperative radiotherapy results of serous endometrial carcinoma: 34 cases during 2003-2014  by Holub, K. et al.
ESTRO 35 2016                                                                                                                                                    S619 
________________________________________________________________________________ 
EP-1320  
Postoperative radiotherapy results of serous endometrial 
carcinoma: 34 cases during 2003-2014 
K. Holub
1Hospital Clínic i Universitari, Radiation Oncology Dpt, 
Barcelona, Spain 
1, A. Rovirosa2, G. Oses1, L. Castilla1, J. Mansilla3, R. 
Llorente1, K. Cortes1, J. Garcia1, S. Garrido1, A. Huguet1, C. 
Castro1, J. Sola1, J. Ordi4, J. Pahisa5, A. Biete1 
2Hospital Clinic i Provincial, Radiation Oncology Dpt, 
Barcelona, Spain 
3Hospital Rebagliati, Radiation Oncology Dpt, Lima, Peru 
4Hospital Clínic i Universitari, Pathology Dpt, Barcelona, 
Spain 
5Hospital Clínic i Universitari, Ginecological cancer Unit, 
Barcelona, Spain 
 
Purpose or Objective: To evaluate post-operative treatment 
results of serous endometrial carcinoma (SEC) comparing two 
histological subtypes (with and without an endometrioid 
component) and its impact on overall survival (OS), local 
control, distant relapses in patients treated from 2003-2014.  
 
Material and Methods: Thirty-four patients (p) with SEC were 
treated with post-operative radiotherapy at our centre. All 
the patients were divided into two groups according to the 
histological subtype: 21p with pure SEC in Group 1, 13p with 
mixed SEC with endometrioid cells in Group 2. All patients 
were staged using 2009-FIGO classification. Group 1: 10-IA, 5-
IB, 1-IIIA, 4-IIIC1, 1-IIIC2. Group 2: 2-IA, 7-IB, 2-IIIA, 1-IIIB, 1-
IIIC1. Pathology. Group 1: Grade (G): G2- in 5p, G-3 in 16p. 
Group 2: Grade: G1 in 1p, G2- in 3p, G-3 in 9 p. Myometrial 
invasion was presented in 10p in Group 1 and 3p in Group 2. 
Median tumour size was 3.6cm in Group 1 and 3.9cm in Group 
2. Vascular and lymphatic space invasion was presented in 5p 
(23.8%) in Group 1 and in 6p (46.2%) in Group 2. 
Radiotherapy: all p received high-dose-rate brachytherapy (1-
3 fractions of 4-7 Gy), and 17/21p in Group 1 and 12/13p in 
Group 2 received external beam irradiation (mean dose of 
45.2Gy in Group 1 and 44.6 Gy in Group 2, after 3D planning 
and 4-field technique tailored to surgical results). 
Chemotherapy: 4-6 cycles of carboplatin + paclitaxel in 8/21 
pts in Group 1 and 6/13 pts in Group 2. 
 
Results: Mean age: 68.7 years (57-81) in Group 1, 70.3 years 
(63-83) in Group 2. Mean follow-up (months): in Group 1: 57 
(7.8-153), in Group 2: 63 (12-117.8). Relapses: No vaginal 
relapses were developed; only 3/34p (8.8%) presented loco-
regional relapse (2p in Group 1 and 1p in Group 2); 8/34 p 
(23.5%) had distant metastasis (3/21 in Group 1 and 5/13 in 
Group 2) and 13/34p (38.2%) had died at the time of the last 
control. The mean OS (months) was 58.9 (range 22.9-138.8) 
in Group 1 and 37.1 (range 12-84.8) in Group 2. The mean 
survival time to metastasis (months) was 38.4 (range 8.2-
70.7) in Group 1 and 19.6 (range 9.5-53) in Group 2. The 
mean survival time to loco-regional relapse (months) was 
27.5 (10.9-16.6) in Group 1 (2p) and 13 in Group 2 (only 1p).  
 
Conclusion: At the time of the last control 61.8%p were 
alive. The main cause of relapse was distant metastases 
followed by loco-regional relapse with no patient showing 
vaginal relapse. The mean OS was substantially longer in 
patients with the pure SEC subtype (58.9 vs. 37.1 months) as 
was the mean survival time to metastasis (38.4 vs. 19.6 
months) possibly due to the higher number of IA stage 
patients. Comparisons of two histological subgroups are 
scarce in the literature. 
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Purpose or Objective: To evaluate treatment results in the 
post-operative treatment of Clear-cell endometrial 
carcinoma (CCEC) related to overall survival (OS), local 
control and distant relapses from 2005 to 2014 
 
Material and Methods: Twenty patients (pts) with CCEC were 
treated at our centre with post-operative radiotherapy. All 
patients were staged after surgery using the 2009-FIGO 
classification: 6-IA, 4-IB, 2-II, 1-IIIA, 4-IIIC1, 2-IIIC2, 1-IVA. 
Pathology. Grade (G): G-I in 2pts, G2- in 5pts, G-3 in 13pts. 
Myometrial invasion was observed in 40% of pts. Median 
tumour size was 3.6cm (range 1.2-6.5cm). Vascular and 
lymphatic space invasion was presented in 25% of pts. 
Histological subtypes: clear cell in 11 pts (55%), clear cell 
mixed with endometrioid in 9 pts (45%). Radiotherapy: all pts 
received high-dose-rate brachytherapy (1-3 fractions of 7-4 
Gy) and 18/20 pts received external beam irradiation (mean 
dose of 45 Gy (44-46Gy) after 3D planning and 4-field 
technique tailored to surgical results). Chemotherapy: 4-6 
cycles of carboplatin + paclitaxel in 8 pts (40%).  
 
Results: The mean age: 67 years (51-79). Mean follow-up: 
4.34 years (range 0.96-9.75 years). Relapses: No pts 
developed vaginal relapse; 6/20 pts (33%) presented loco-
regional relapse, 4/20 (20%) pts had distant metastasis (two 
with pelvic relapse 2/20 (10%); all 6 pts with relapse died 
(33%). The mean OS of 33.6 months (range 16.3-74.4 
months). The mean survival to metastasis was 38.4 months 
(range 8.2-70.7 months) and 20.64 months (8.2-32months) to 
loco-regional relapse. No patient was lost to follow-up. 
 
Conclusion: At the time of the last control 70% of patients 
(14/20) were alive and without relapse. The main cause of 
relapse was loco-regional followed by distant metastases, 
with no patients showing vaginal relapse. The results of this 
study seem to be similar to those reported in the literature. 
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Purpose or Objective: To evaluate the clinical features and 
treatment outcomes of isolated para-aortic lymph node 
(PALN) recurrence in cervical cancer patients, and analyze 
prognostic factors for overall survival 
 
Material and Methods: Between 1992 and 2014, 1302 cervical 
cancer patients received radiotherapy at two institutions, 
Seoul National University Hospital and Seoul National 
University Bundang Hospital. Of these, 29 had isolated PALN 
recurrence. The median age at recurrence was 62 years 
(range, 34-81 years). Twenty-seven of 29 patients received 
salvage treatment: 16 received sequential or concurrent 
chemoradiotherapy, 6 radiotherapy to the para-aortic region, 
4 chemotherapy alone, and 1 chemotherapy followed by 
salvage operation. 
 
Results: The median follow-up duration after salvage 
treatment was 17.4 months (range, 1.1-139.2 months). 
Treatment failure after salvage treatment occurred in 10 of 
27 patients. The 5-year progression-free and overall survival 
rates of all patients were 25.1% and 30.5%, respectively. 
Disease-free interval >=24 months and upfront radiotherapy 
(or chemoradiotherapy) were good prognostic factors for 
